Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

DMAA vs PFE

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares

Shell Companies

Financial ServicesNASDAQ • US
Market Cap$111M
5Y Perf.+6.3%
PFE
Pfizer Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$146.02B
5Y Perf.-2.9%

DMAA vs PFE — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DMAA logoDMAA
PFE logoPFE
IndustryShell CompaniesDrug Manufacturers - General
Market Cap$111M$146.02B
Revenue (TTM)$0.00$63.31B
Net Income (TTM)$6M$7.49B
Gross Margin69.3%
Operating Margin23.4%
Forward P/E8.7x
Total Debt$662.00$67.42B
Cash & Equiv.$1K$1.14B

DMAA vs PFELong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DMAA
PFE
StockFeb 25May 26Return
Drugs Made In Ameri… (DMAA)100106.3+6.3%
Pfizer Inc. (PFE)10097.1-2.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: DMAA vs PFE

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PFE leads in 3 of 3 categories, making it the strongest pick for dividend income and shareholder returns and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
The Banking Pick

DMAA is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.00, current ratio 6.27x
  • Beta 0.00, current ratio 6.27x
Best for: sleep-well-at-night and defensive
PFE
Pfizer Inc.
The Long-Run Compounder

PFE carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 28.5% 10Y total return vs DMAA's 6.4%
  • 6.7% yield; 15-year raise streak; the other pay no meaningful dividend
  • +21.1% vs DMAA's +5.0%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
DividendsPFE logoPFE6.7% yield; 15-year raise streak; the other pay no meaningful dividend
Momentum (1Y)PFE logoPFE+21.1% vs DMAA's +5.0%
Efficiency (ROA)PFE logoPFE3.6% ROA vs DMAA's 2.4%

DMAA vs PFE — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DMAADrugs Made In America Acquisition Corp. Ordinary Shares

Segment breakdown not available.

PFEPfizer Inc.
FY 2025
Biopharma Segment
97.8%$61.2B
Segment Reporting, Reconciling Item, Corporate Nonsegment
2.2%$1.4B

DMAA vs PFE — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDMAALAGGINGPFE

Income & Cash Flow (Last 12 Months)

Insufficient data to determine a leader in this category.

PFE and DMAA operate at a comparable scale, with $63.3B and $0 in trailing revenue.

MetricDMAA logoDMAADrugs Made In Ame…PFE logoPFEPfizer Inc.
RevenueTrailing 12 months$0$63.3B
EBITDAEarnings before interest/tax-$726,546$21.0B
Net IncomeAfter-tax profit$6M$7.5B
Free Cash FlowCash after capex-$414,132$9.5B
Gross MarginGross profit ÷ Revenue+69.3%
Operating MarginEBIT ÷ Revenue+23.4%
Net MarginNet income ÷ Revenue+11.8%
FCF MarginFCF ÷ Revenue+15.0%
Rev. Growth (YoY)Latest quarter vs prior year+5.4%
EPS Growth (YoY)Latest quarter vs prior year-9.5%
Insufficient data to determine a leader in this category.

Valuation Metrics

Evenly matched — DMAA and PFE each lead in 1 of 2 comparable metrics.

On an enterprise value basis, PFE's 10.4x EV/EBITDA is more attractive than DMAA's 9999.0x.

MetricDMAA logoDMAADrugs Made In Ame…PFE logoPFEPfizer Inc.
Market CapShares × price$111M$146.0B
Enterprise ValueMkt cap + debt − cash$111M$212.3B
Trailing P/EPrice ÷ TTM EPS-189.29x18.88x
Forward P/EPrice ÷ next-FY EPS est.8.66x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple9999.00x10.44x
Price / SalesMarket cap ÷ Revenue2.33x
Price / BookPrice ÷ Book value/share1.68x
Price / FCFMarket cap ÷ FCF16.09x
Evenly matched — DMAA and PFE each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

Evenly matched — DMAA and PFE each lead in 2 of 4 comparable metrics.

On the Piotroski fundamental quality scale (0–9), PFE scores 7/9 vs DMAA's 3/9, reflecting strong financial health.

MetricDMAA logoDMAADrugs Made In Ame…PFE logoPFEPfizer Inc.
ROE (TTM)Return on equity+8.3%
ROA (TTM)Return on assets+2.4%+3.6%
ROICReturn on invested capital+7.5%
ROCEReturn on capital employed+9.0%
Piotroski ScoreFundamental quality 0–937
Debt / EquityFinancial leverage0.78x
Net DebtTotal debt minus cash$661$66.3B
Cash & Equiv.Liquid assets$1,351$1.1B
Total DebtShort + long-term debt$662$67.4B
Interest CoverageEBIT ÷ Interest expense4.02x
Evenly matched — DMAA and PFE each lead in 2 of 4 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — DMAA and PFE each lead in 3 of 6 comparable metrics.

A $10,000 investment in DMAA five years ago would be worth $10,643 today (with dividends reinvested), compared to $8,517 for PFE. Over the past 12 months, PFE leads with a +21.1% total return vs DMAA's +5.0%. The 3-year compound annual growth rate (CAGR) favors DMAA at 2.1% vs PFE's -6.9% — a key indicator of consistent wealth creation.

MetricDMAA logoDMAADrugs Made In Ame…PFE logoPFEPfizer Inc.
YTD ReturnYear-to-date+2.1%+5.4%
1-Year ReturnPast 12 months+5.0%+21.1%
3-Year ReturnCumulative with dividends+6.4%-19.4%
5-Year ReturnCumulative with dividends+6.4%-14.8%
10-Year ReturnCumulative with dividends+6.4%+28.5%
CAGR (3Y)Annualised 3-year return+2.1%-6.9%
Evenly matched — DMAA and PFE each lead in 3 of 6 comparable metrics.

Risk & Volatility

DMAA leads this category, winning 2 of 2 comparable metrics.

DMAA is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than PFE's 0.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DMAA currently trades 100.0% from its 52-week high vs PFE's 89.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDMAA logoDMAADrugs Made In Ame…PFE logoPFEPfizer Inc.
Beta (5Y)Sensitivity to S&P 5000.00x0.49x
52-Week HighHighest price in past year$10.60$28.75
52-Week LowLowest price in past year$10.09$21.97
% of 52W HighCurrent price vs 52-week peak+100.0%+89.3%
RSI (14)Momentum oscillator 0–10071.143.9
Avg Volume (50D)Average daily shares traded166K33.3M
DMAA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

PFE is the only dividend payer here at 6.69% yield — a key consideration for income-focused portfolios.

MetricDMAA logoDMAADrugs Made In Ame…PFE logoPFEPfizer Inc.
Analyst RatingConsensus buy/hold/sellHold
Price TargetConsensus 12-month target$27.40
# AnalystsCovering analysts39
Dividend YieldAnnual dividend ÷ price+6.7%
Dividend StreakConsecutive years of raises15
Dividend / ShareAnnual DPS$1.72
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

DMAA leads in 1 of 6 categories — strongest in Risk & Volatility. 3 categories are tied.

Best OverallDrugs Made In America Acqui… (DMAA)Leads 1 of 6 categories
Loading custom metrics...

DMAA vs PFE: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is DMAA or PFE a better buy right now?

Pfizer Inc.

(PFE) offers the better valuation at 18. 9x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Pfizer Inc. (PFE) a "Hold" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — DMAA or PFE?

Over the past 5 years, Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) delivered a total return of +6. 4%, compared to -14. 8% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: PFE returned +28. 5% versus DMAA's +6. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — DMAA or PFE?

By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.

Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus Pfizer Inc. 's 0. 49β — meaning PFE is approximately Infinity% more volatile than DMAA relative to the S&P 500.

04

Which has better profit margins — DMAA or PFE?

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus 0. 0% for Drugs Made In America Acquisition Corp. Ordinary Shares — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 0. 0% for DMAA. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — DMAA or PFE?

In this comparison, PFE (6.

7% yield) pays a dividend. DMAA does not pay a meaningful dividend and should not be held primarily for income.

06

Is DMAA or PFE better for a retirement portfolio?

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 6. 7% yield). Both have compounded well over 10 years (PFE: +28. 5%, DMAA: +6. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between DMAA and PFE?

These companies operate in different sectors (DMAA (Financial Services) and PFE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DMAA is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while DMAA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

DMAA

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
Run This Screen
Stocks Like

PFE

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.